Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease.
about
Cardioselective beta-blockers for chronic obstructive pulmonary diseaseCOPD and its comorbidities: Impact, measurement and mechanismsExcess costs of comorbidities in chronic obstructive pulmonary disease: a systematic reviewEffect of beta-blockers on exacerbation rate and lung function in chronic obstructive pulmonary disease (COPD).Chronic obstructive pulmonary disease after myocardial infarction in the community.Impact of chronic obstructive pulmonary disease on morbidity and mortality after myocardial infarctionBeta-blockers reduced the risk of mortality and exacerbation in patients with COPD: a meta-analysis of observational studies.In-hospital and one-year mortality and their predictors in patients hospitalized for first-ever chronic obstructive pulmonary disease exacerbations: a nationwide population-based studyESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with theUpdate in hospital medicine for the general internist 2010-2011.Association between β-blocker therapy and outcomes in patients hospitalised with acute exacerbations of chronic obstructive lung disease with underlying ischaemic heart disease, heart failure or hypertension.Ultrafast imaging of the entire chest without ECG synchronisation or beta-blockade: to what extent can we analyse the coronary arteries?The impact of COPD on management and outcomes of patients hospitalized with acute myocardial infarction: a 10-year retrospective observational study.β-blocker use and mortality in COPD patients after myocardial infarction: a Swedish nationwide observational study.Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary diseaseCoronary artery disease is under-diagnosed and under-treated in advanced lung disease.Use of beta-adrenoceptor antagonists in older patients with chronic obstructive pulmonary disease and cardiovascular co-morbidity: safety issues.Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditionsCardiovascular injury and repair in chronic obstructive pulmonary disease.Drugs potentially affecting the extent of airways reversibility on pulmonary function testing are frequently consumed despite guidelinesImpact of beta2-agonists, beta-blockers, and their combination on cardiac function in elderly male patients with chronic obstructive pulmonary disease.Beta-blockers and health-related quality of life in patients with peripheral arterial disease and COPD.Underuse of β-blockers in heart failure and chronic obstructive pulmonary disease.β-Blockers are associated with a reduction in COPD exacerbations.Acute exacerbation of chronic obstructive pulmonary disease: cardiovascular links.Link between chronic obstructive pulmonary disease and coronary artery disease: implication for clinical practice.Temporal Trends in Treatment and Outcomes of Acute Myocardial Infarction in Patients With Chronic Obstructive Pulmonary Disease: A Nationwide Population-Based Observational Study.Beta-blocker therapy in patients with left ventricular systolic dysfunction and chronic obstructive lung disease in an ambulatory care setting.Comparison between ATS/ERS age- and gender-adjusted criteria and GOLD criteria for the detection of irreversible airway obstruction in chronic heart failure.Effects of intravenous and oral β-blockade in persistent asthmatics controlled on inhaled corticosteroids.Beta-blockers are safe in patients with chronic obstructive pulmonary disease, but only with caution.The role of beta-blockers in the management of chronic obstructive pulmonary disease.Commencement of cardioselective beta-blockers during hospitalisation for acute exacerbations of chronic obstructive pulmonary disease.Tolerability of Bisoprolol on Domiciliary Spirometry in COPD.Cardiopulmonary interactions with beta-blockers and inhaled therapy in COPD.Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease.The prognostic influence of chronic obstructive pulmonary disease in patients hospitalised for chronic heart failure.Outcome of patients with chronic obstructive pulmonary disease and severe coronary artery disease who had a coronary artery bypass graft or a percutaneous coronary intervention.Association of beta-blocker treatment with mortality following myocardial infarction in patients with chronic obstructive pulmonary disease and heart failure or left ventricular dysfunction: a propensity matched-cohort analysis from the High-Risk MyESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the
P2860
Q24245649-AE4A7B4E-DE83-4650-8E62-516898C2EC55Q26786812-08742B3A-D3B6-4C16-817E-CE16012468A2Q26828976-12B1F0FD-FFA9-4C77-BDC8-EE29B6981BCBQ33814586-B5516C24-DF16-475B-90D6-F194A557520EQ33964930-FDCB6CBA-6C2D-4B60-B57D-2F5B2CC93B01Q34304837-667EC493-577E-4AB8-BA08-EAF5E9C868CDQ34575920-18C68FF7-A01B-496C-9827-04CF7E5C4E00Q34663530-B95BB0F3-FD89-4447-A6FC-7BC9AC9C5014Q34830023-CE8D838A-D484-4B6E-AD40-F1E32D9ECF81Q35606877-B4BC4656-4871-46B0-9BFA-15E98C51A0C4Q35680413-20E2FBC2-9F38-4E2F-81A9-E7910554A1F7Q35798655-C202F7A6-7158-4F0B-A030-1145750898FFQ36009093-C3BCE843-D1A4-41B6-B479-0E9A340F9A46Q36085731-26F5D614-9CEB-4A0A-B7E8-BCEE5CF26A94Q37047304-C37B6698-A811-4C81-91F9-CCCF05738C03Q37066051-33F29CD1-319F-4DEE-B128-DE0D30107592Q37079088-F466094B-B5FA-46CA-BCCD-6DDC2BCABC65Q37082599-EC4C5AB4-2039-424E-8E08-7C1FB3B24943Q37098445-996967AD-9F4F-43BF-A627-3A083616A4D0Q37099575-A38BFD94-A663-4CF7-8942-C1CD1E41524DQ37198408-426FF35A-84AF-41C2-A2F4-AE30B51017A7Q37199663-91A18D0D-A610-43A4-A69E-9FBC44E5DBA3Q37471531-CB7C906A-33F0-4FD9-829E-1C7954FDB5D9Q37499919-AB83AA9D-39FD-4172-A987-43A8F000B643Q37644823-2727074C-AAE9-4730-B8C8-A47B42611860Q37964807-144716C3-1C9B-4B07-9701-28C297836823Q41103839-AC16AFA4-178A-425A-BD56-FE59296A8DC6Q42794601-49B8EC4C-D6E9-4975-8523-B7D06CD041EDQ45301370-06E22CC4-643A-4BA6-A3F5-7014C85A82F7Q45950168-568FD071-A477-4FE2-AB46-5070C4882304Q46363629-E7372108-6DB9-4BF7-BDCE-7E7F241DDC1CQ47676572-AE40B1D9-A797-459E-976A-F5EE43C82003Q47721405-E00B9453-A871-4649-A96F-A02C9949C7FCQ47744550-6ECB4500-7AF1-4B8F-9015-47B6E633D573Q47746323-7C3F20A7-CF0C-4D6E-AD4E-BC199B5C2A86Q47792766-50D402DE-58B0-403F-A8E4-EB3A95EF2C09Q51746421-E15688E3-D86F-4630-8C5B-FB38A2AA6B8EQ54325324-D3FF23FF-0E4E-48FB-83C6-DE35CB9D4550Q54597749-A5B1B140-3073-4619-959E-CB4E76636AC7Q55050673-F64963FD-68D1-48C8-922B-CC504E90AF0B
P2860
Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Under-use of beta-blockers in ...... obstructive pulmonary disease.
@ast
Under-use of beta-blockers in ...... obstructive pulmonary disease.
@en
type
label
Under-use of beta-blockers in ...... obstructive pulmonary disease.
@ast
Under-use of beta-blockers in ...... obstructive pulmonary disease.
@en
prefLabel
Under-use of beta-blockers in ...... obstructive pulmonary disease.
@ast
Under-use of beta-blockers in ...... obstructive pulmonary disease.
@en
P2093
P2860
P356
P1476
Under-use of beta-blockers in ...... obstructive pulmonary disease.
@en
P2093
P2860
P304
P356
10.1093/QJMED/HCI080
P407
P577
2005-06-13T00:00:00Z